NCT07157007Phase 2Recruiting

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

Study sponsor: Traws Pharma, Inc. · TRAW

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-02Estimated

Enrollment · participants90Estimated

Source updated2026-01-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-21 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2025-12

+ Updated value

2026-02

Check registry source

Posted 2025-12-03 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Not yet recruiting

+ Updated value

Recruiting

Check registry source

Study details

Conditions studied

COVID - 19

Treatments or interventions studied

Ratutrelvir (83-0060) non-randomisedDrug
PaxlovidDrug
Ratutrelvir (83-0060)Drug

Primary outcomes · main study measures

measure: Safety based on adverse events incidence; description: Adverse events incidence will be described using descriptive statistics methods; timeFrame: 28 days; measure: Safety based on adverse events severity; description: Adverse events severity will be assessed by current version of CTCAE; timeFrame: 28 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history